On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now Blog

All posts by Christopher

Talent Acquisition Week Offers a Unique Online Learning & Networking ExperienceTalent Acquisition Week Offers a Unique Online Learning & Networking Experience

GSMI’s Talent Acquisition Week offers the most comprehensive learning experience, combining sourcing, recruiting, and employer branding strategies together in a fully immersive digital conference experience, and will be held on July 25 – 29th, 2022. The Global Strategic Management Institute (“GSMI”) is a fully digital, cutting-edge conference production company with a footprint in over 100 countries and strives to disrupt policy, champion innovation, and combine the entrepreneurial spirit with the most powerful technological movements. Esteemed Sponsors of GSMI’s Talent Acquisition Week include Recruit Roster, Recruitics, Gem, Circa, Findem, Globalization Partners, Entelo, RippleMatch, Builtin, Jobvite, Verified Credentials, BrightHire, Beamery, SmartRecruiters, Eightfold.ai, Sense, and Clinch. The full list of sponsors and partners is available here. The event will host eminent speakers from across the industry to share their invaluable insights with a focus on advancing the best digital practices and discussing the latest trends in talent acquisition and human capital management through engaging keynote sessions, informative presentations, lively panel discussions, spotlight sessions, and dedicated networking opportunities. Key pillars of the 5-day conference include:
  • Day 1: Talent Sourcing Strategies Summit
  • Day 2: Social Recruiting Strategies Conference #SRSC
  • Day 3: Talent Data Analytics
  • Day 4: Employer Branding Strategies Conference #EBrandCon
  • Day 5: Diversity, Equity, Inclusion, and Belonging (“DEIB”)
Why Should You Attend? The 5-day event will feature 50+ sessions from leading TA practitioners sharing invaluable insights on utilizing innovative strategies, the latest must-know TA tools, and state-of-the-art technology to reimagine talent attraction.  Speakers will also outline day-to-day business challenges and tailored solutions to help power company-specific TA strategies. The event will host industry stalwarts including Camille Tate, Head of Talen, Strava; Steven Kosakow, Vice President of Global Talent Acquisition, Sophia Genetics; Jimmy Zhang, Vice President, Head of Global Talent Acquisition, Takeda; Aditya Pal Singh, Director, Head Talent Acquisition, Informatica; and a roster of other distinguished speakers from several leading organizations including Google, Amazon, Twitter, and MetLife to name a few. Day 1 opening remarks will be made by Mike “Batman” Cohen, the Founder of Wayne Technologies, a contract sourcing and recruitment training organization, to set the stage for the myriad talent sourcing strategies to be presented during the week. The Talent Acquisition Week enables attendees to interact by asking questions in virtual rooms, streaming live lectures, and even networking one-on-one to form long-term partnerships. In addition, the 600+ attendees will engage directly with invited speakers and network with human resources peers through scheduled Networking in the Lounge and Coffee Talk sessions. Attendees will also have access to all sessions and recordings. To register for the event, to make inquiries about group discounts, or discuss speaking opportunities,  contact Jessica Vargas, or visit Attendee Registration. For sponsorship opportunities, contact Kelly Hara.

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Licensee Expands Manufacturing Agreements to Include Europe, Japan, and South Africa

  • Lexaria’s patented DehydraTECH(TM) enhancement technology targets key market segments including nicotine replacement, CBD, cardiovascular and antiviral drugs, human hormones, and PDE5 inhibitors
  • DehydraTECH-enabled drug and consumer products provide faster delivery times, increased bioavailability, increased brain absorption, improved drug potency, lower administration costs, and mask unwanted tastes
  • The global CBD market was valued at $5.18 billion in 2021 and is expected to grow at a CAGR of 16.8% from 2022 to 2030, resulting in a revenue forecast of $22.05 billion by 2030
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that Boldt Runners Corporation, licensee of its patented DehydraTECH(TM) technology and owner of the Cannadips Brand, has expanded its manufacturing agreements to include Europe, Japan, and South Africa. Cannadips CBD dip pouches are the leading cannabidiol (“CBD”) pouch in the United States. They are a tobacco-free and nicotine-free dip alternative that provides an effective way for consumers to enjoy CBD. Cannadips is sold in over 6,500 retail locations across the United States, including direct-to-consumer online purchases (https://ibn.fm/wdJ3s). Every tin of Cannadips product features DehydraTECH enhancement technology and results from longstanding collaboration and product design. “We are delighted with the expansion of the Cannadips brand outside of the USA. We continue to work with the Cannadips team on the infusion of exciting new formulations to meet the needs of adult consumers’ changing preferences and will endeavor to always remain one step ahead of the competition,” Lexaria Bioscience CEO Chris Bunka stated. Lexaria’s DehydraTECH enhancement technology is covered by 25 issued and more than 50 pending patents spanning 40 countries worldwide. The United States Patent and Trademark Office issued the first patent for the technology in October 2016. The technology was designed to formulate and deliver lipophilic (fat-soluble) drugs and active ingredients to increase effectiveness and improve the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. DehydraTECH-enabled drug and consumer products provide a myriad of benefits to the consumer, including:
  • Faster delivery times – the effects of the DehydraTECH-enabled drug or product are felt by most consumers in a matter of minutes
  • Increased bioavailability – the technology provides greater absorption into the bloodstream
  • Increased brain absorption – through animal testing, significant improvement has been seen in the quantity of the drug delivered across the blood-brain barrier
  • Improved drug potency – more of the ingested product is made available to the body, with lower doses required to achieve the desired effect
  • Reduced drug administration costs – lower dosages can lower the drug cost
  • Masking of unwanted taste – the DehydraTECH technology eliminates or reduces the need to add sweeteners for tolerability
As the relationship between Lexaria and the Cannadips brand continues to flourish through international product sales, it opens new channels of growth for Lexaria’s revenues. Pete Diatelevi, CEO of Boldt Runners Corporation, said, “We are extremely grateful for our longstanding relationship with Lexaria and look forward to our continued expansion into new channels, geographies, and product formats.” The expansion comes as the global CBD market is continues growing, being estimated to reach $22.05 billion by 2030, growing at a CAGR of 16.8% from the $5.18 billion value reported in 2021 (https://ibn.fm/az46i). Lexaria is leveraging several key market segments through its ongoing research and development efforts, including nicotine replacement, CBD, cardiovascular and antiviral drugs, human hormones, and PDE5 inhibitors. Since 2016, Lexaria’s DehydraTECH enhancement technology has repeatedly demonstrated, with nicotine and cannabinoids, the ability to increase the bio-absorption through ranges of five to ten times, reducing the time of onset from one to two hours to a matter of minutes while masking intolerable tastes. The company is also further evaluating the administration of DehydraTECH-enabled active pharmaceutical ingredients including antivirals, cannabinoids, and nicotine. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Friendable Inc. (FDBL) Offers Independent Artists a 360-Degree Platform for Production, Distribution, and Marketing Music, While Retaining Full Control of Their Music

  • 68% of the music industry market is dominated by major record labels, with independent labels and self-releasing artists rising to 27% of the market share
  • The three primary record labels dominate the global music industry, valued at $53.77 billion in 2018 and expected to reach $65.17 billion by 2023
  • 90% of artist revenue is lost to the record labels, management, and streaming service fees
  • Fan Pass Live’s 360-degree artist offering allows independent musicians the ability to produce, distribute, and market their music, keep control of their art, and receive revenue through various avenues
For decades, the only way to make it big in the music industry was to sign with a major record label. Although 68% of the market is still dominated by three key labels – Universal Music Group, Sony Music Entertainment, and Warner Music Group – independent music labels and self-releasing artists have entered the arena, claiming close to 27% of the market (https://ibn.fm/TL8wd). While numerous factors are at play, the increase in the streaming market plays a vital role in how musical artists distribute their music. Over the past decade and a half, the streaming market has seen a dramatic increase in the music industry revenue it is responsible for, growing from 1% in 2005 to 83% in 2020 (https://ibn.fm/fOTqo). The digital service provider (“DSP”) with the most influence in the streaming market in 2021 was Spotify, holding 31% of the streaming market share (https://ibn.fm/BvELF). The global music industry market was valued at $53.77 billion in 2018 and is expected to reach $65.17 billion by 2023 (https://ibn.fm/FErBm). However, the primary beneficiary of this revenue is still the major record labels and streaming industry dominators, not the artists themselves. The revenue independent artists lose to these factors is close to 90% after paying managers, labels, distribution, and marketing fees. Seeing an unmet need in the independent music artist industry, Friendable (OTC: FDBL), a mobile technology and marketing company, released its flagship product, Fan Pass Live artist platform, in July 2020. Fan Pass Live allows independent artists to perform for and interact with fans without label control or costs. In January 2022, Friendable completed the acquisition of Artist Republik and FeaturedX to create the ultimate “anti-label,” 360-degree solution for independent artists. Traditionally, when signing with a record label, artists would sign over the rights and majority of their royalties to the record label. With Artist Republik, artists can distribute their music, keep 100% of the royalties, and keep the rights to the music they produce. Artists receive royalty payouts quarterly, accessible through their Distribution Dashboard on the app. Artists are also afforded the opportunity to distribute and grow via Spotify and Soundcloud. According to Fan Pass Live’s Instagram, 23% of independent music artists lose money on their music projects, with less than 5% making a living from the music industry. Only 72% of those artists report making a profit, but it is still not enough for them to live on (https://ibn.fm/Yk3oc). That is what makes Fan Pass Live different; it offers independent artists:
  • Scheduled events promoted on the company’s social media platforms
  • Five different avenues for collecting revenue
  • Access to advanced analytics
  • Custom merchandise and design
  • 100% revenue from Livestream performances
With promotion and marketing playing a primary role in getting an independent artist’s name out there, Fan Pass Live’s offering of Livestream performances gets artists the exposure necessary for fans and potential fans to get to know the artist and their music. The 360-degree artist offering provides the tools for independent artists to reclaim their music, make money, and connect with fans worldwide. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

FingerMotion Inc. (NASDAQ: FNGR) Optimizing its Product Mix and Exploring New Opportunities in Huge and Growing Chinese Market

  • FingerMotion posted a 37% YOY revenue growth for the 2021 financial year
  • The company’s Telecommunications Products and Services category posted the highest growth at 170%
  • The company looks to build on this performance by capitalizing on the opportunities within China and, more specifically, the mobile payment and mobile recharge platform solutions market
  • Its successful strategy is based upon pushing gross margins by offering new products and services and improving existing ones
In June 2022, FingerMotion (NASDAQ: FNGR) released its financial results for the year ended February 28, 2022. Of note in the report was the 37% year-over-year (“YOY”) growth in overall revenue, mainly fueled by the growth of Telecommunications Products and Services, which posted a 170% growth from the previous year (https://ibn.fm/nCpFs). When making the announcement, Martin Shen, FingerMotion’s Chief Executive officer (“CEO”), noted: “We have been able to steadily increase our margins by optimizing our product mix between Top-up and SMS.” “While our biggest challenge continues to be access to non-dilutive capital, we remain steadfast in our belief that we will reach profitability in the near future,” he added (https://ibn.fm/KsNW5). Founded in 2016, FingerMotion has grown to be one of China’s leading mobile payment and recharge platform solutions. So far, it serves over a billion users in the Chinese market, spreading its operations across the region. Being in such a lucrative market, FingerMotion’s management recognizes the opportunities available, especially given the wide adoption of mobile phones to the proliferation of mobile payments. The management believes this will be integral in growing the company and creating even more value for its shareholders. China is seeing an ongoing boom in mobile phone adoption. By December 2020, over 1.22 billion people had subscribed to mobile services within the country, representing 83% of the region’s population. By comparison, the global average mobile phone penetration at the time stood at 66%, making China one of the most developed mobile markets in the world (https://ibn.fm/DvxYA). Experts project that this number will rise significantly over the coming years, mainly given the rapid deployment of 5G in China, along with the massive uptake of smartphones in the country. This presents a tremendous opportunity for FingerMotion, particularly since one of its key initiatives is to keep pushing gross margins higher. The company is constantly working on new product offerings while exploring ways to improve existing ones. This has seen the introduction of the mobile protection program, along with the overall improvement of the Telecommunications Products and Services business. FingerMotion also looks to capitalize on the growing adoption of mobile payments, following President Xi Jinping’s encouragement of mobile payments and financial technology platforms to “play a bigger role” in strengthening China’s economy (https://ibn.fm/2ElU2). With its central competencies in mobile payment and mobile recharge platform solutions, FingerMotion is poised to benefit significantly from this emerging market and its opportunities. Going forward, FingerMotion looks to capitalize on its strengths while exploring new avenues for creating shareholder value and creating new revenue streams. It looks to build on the performance from the previous financial year, with the goal of achieving profitability soon. The company plans to follow through with its mobile protection program, whose rollout is on schedule, while also maintaining critical collaborations with its telecom partners and Chinese subsidiaries to maintain profitability throughout the year. “One of our key initiatives is to keep pushing gross margins higher, and we have been quite successful by optimizing our product offerings,” Mr. Shen noted. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

Cepton, Inc. (NASDAQ: CPTN) Solidifies Its Detroit Presence with New Office in Troy; Poised to Be Integral Part of Latest Auto Trends

  • Cepton has opened a new dedicated automotive office in Metro Detroit – a clear sign of its growing relationship with General Motors and the American auto industry
  • Company solidifies itself as a key player in lidar; Metro Detroit office serves as automotive hub providing local support to OEM and Tier 1 partners
  • Cepton boasts collaboration with Ford, expands its ongoing partnership with Koito Manufacturing, a leading tier-1 automotive lighting supplier, and remains engaged with the top 10 global automakers
“I’m incredibly proud that our Silicon Valley company, Cepton, has earned Detroit’s trust,” said Dr. Jun Pei, Cepton (NASDAQ: CPTN) Co-Founder and CEO, following an announcement that this leader in high-performance MMT(R) lidar solutions opened a newly renovated office in Metro Detroit (Troy, MI) (https://ibn.fm/mm3WC). The 4,800-square-foot office will house the company’s key business functions such as product and program management, business development, application engineering, sales, and corporate marketing. Although Cepton has had a presence in Detroit since its inception in 2016, it wasn’t until the company secured the industry’s largest ADAS lidar series production award with General Motors in 2019 that it began renovating and expanding the office. To accommodate the team’s rapid growth following this key achievement, Cepton relocated its previous office in the Detroit area to Troy so it can continue to forge close relationships with automakers centered around this heart of the US auto industry (https://ibn.fm/UxCFZ). A strong team close to automotive OEMs and tier 1s is essential for the company. In the words of Brunno Moretti, Cepton’s Vice President of Product and head of the Detroit office, making lidar an integral ‘auto part’ in every passenger car cannot be achieved without close collaboration with the company’s automotive customers. “Having a strong presence in Detroit not only enables us to keep up with the latest trend in the industry but also makes us part of that trend – we are here to demonstrate how lidar is essential to the future of mobility, with our product experts driving informative communications and our application engineers working in the field,” he said. In a bid to deepen its relationships and engagements with leading automotive OEMs, Cepton developed a seasoned team in its Troy office and continues to recruit talent in both Detroit and Silicon Valley. Cepton currently has around twenty openings across key business segments, including hardware and software engineering, program management, application, safety, quality, and reliability. “The Detroit office will serve as the automotive hub for Cepton, and we expect the team to grow to ensure we provide local support to our OEM and Tier 1 partners,” Brunno Moretti added. As a provider of state-of-the-art lidar-based solutions with the mission to become one of the most prominent international players in the lidar space, Cepton has built what seems to be a truly global footprint. In addition to the San Jose, Calif., headquarters and the newly opened Troy operations, the company runs offices across the globe – from Germany and Canada to Japan, India, and China. Cepton appears to be successful in forging strong business ties with the auto industry’s key players. In addition to General Motors, the company also boasts an ongoing collaboration with Ford and engagements with the other top 10 automakers across the globe, as well as a five-year partnership with Koito, a leading automotive lighting tier-1 supplier. The company recently announced its intent to expand its existing collaboration with Koito to include certain future Cepton long-range and near-range lidar products. The expanded partnership is intended to also include joint go-to-market activities with select automotive customers, initially targeting Japanese automotive OEMs (https://ibn.fm/OQrMO). “Our expanded footprint will help us reach our goal of making lidar a standard safety feature in the cars of today and the key component in the autonomous vehicles of the future,” concluded Dr. Jun Pei, revealing the company’s aggressive business aspirations. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing healthy organs) suggests joint-homing peptides could deliver therapeutics or fusion imaging nanoparticles to specific diseased tissues. Better imaging, lower radiation and precision, targeted dosing could enhance the therapeutic effect of current and future therapeutics and decrease potential systemic toxicity and adverse reactions. According to the National Library of Medicine (“NLM”), “drug side-effects, or adverse drug reactions (“ADR”), have become a major healthcare concern … serious drug side-effects are estimated to be the fourth leading cause of death in the US, resulting in 100,000 deaths per year.” An adverse drug reaction is a “response to a drug which is noxious and unintended and which occurs at doses normally used …  for prophylaxis, diagnosis or therapy of disease ….” NLM describes various ADR events and effects:
  • Adverse events occurring when “desired therapeutic effects can have additional negative consequences,” i.e., blood pressure drugs causing dizziness if blood pressure drops too low, necessitating a “narrow therapeutic window” for appropriate dosing.
  • Adverse effects due to a target that “serves multiple purposes in different tissues of the body,” such as chemotherapeutics that kill all fast-growing cells including, for instance, “precursors to immune cells,” thereby suppressing the immune system. “Side effects due to the therapeutic drug target’s presence in multiple cell and tissue types … lead to attempts to develop better-targeted therapeutic agents that more specifically target the desired pathway or site of disease.
  • When a drug binds to unintended targets, this refers to off-targets and can produce ADRs and side effects. Off-target effects “are frequently not known or discovered until after observing an adverse event or side effect … in other cases, the specific target responsible for a side effect is not clear.”
Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic process or joint disease. Current treatment for arthritis has side effects that include nausea, vomiting, diarrhea, tinnitus, hair loss, seizures, fever, congestion, unusual lumps or masses and more. OTC arthritis therapeutics, such as common NSAIDs, can produce stomach ulcers, dizziness and indigestion and can have unpredictable results with other medications. Silo’s novel inventions could greatly limit or eliminate these problems. Silo and UMB are also investigating central nervous system (“CNS”) homing peptides to deliver targeted payloads of psilocybin for treating Multiple Sclerosis (“MS”) and other neuroinflammatory diseases. These peptides are designed to address numerous challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (“CNS”), and can be used as an imaging tool for inflammation of the spinal cord. Silo CEO Eric Weisblum said, “The ability to deliver conventional and novel therapeutic compounds directly to targeted areas of the body with homing-peptide technology could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed. There is a tremendous need for creative and unique therapeutics for patients suffering from debilitating diseases … ” Drug delivery systems for the diagnosis and/or therapy of various diseases – Current Neuropharmacology, 2016, Vol. 14, No. 4 For Silo Pharma’s most recent news, click here. Silo Pharma 560 Sylvan Avenue, Suite 3160 Englewood Cliffs, NJ 07632 For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

Emerging iGaming Technology Trends Fuel Golden Matrix Group Inc.’s (NASDAQ: GMGI) B2B Growth Strategy

  • Enhanced graphics, Gamification, AI-powered loyalty systems and data analytics redefining iGaming experience and generating higher player yields for online operators.
  • GMGI sets industry standard, offers 10,000+ games across 25+ providers
  • Company provides highly configurable, modular, white-label, turnkey gaming platforms compatible with all major operating systems, browsers, devices
  • Company recently reported 221% Q2-2022 growth, 15 consecutive profitable quarters
Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, continues its steady growth trajectory by leveraging several emerging technology trends. In particular, the company is leveraging its go-to Loyalty platform that incorporates a Gamification component. Gamification adds an extra layer of player engagement to a regular casino experience incorporating social game type concepts into gambling Environments. When users earn rewards or loyalty points in their user account, they become more engaged. Not only does it bring a sense of self-fulfilment to obtain a new ranking or free giveaway, but it also triggers the players drive for competition and ongoing loyalty. This is why adding loyalty points, leader boards, VIP status and rewards to an online casino works so well. As modern as online casinos may look, traditional slot machines do not offer the evolving experience that digital platforms do. Giving customers more of an interactive experience through screens is something the newer generation continually grows up with (https://ibn.fm/IWUiG). Conventional casinos lack the advantage of self-marketing within an interphase, giving players a reason to achieve a “power up” or creation tools incentive to continue using the products in order to achieve more. This use of gamification resembles a lot in what you see in modern gaming, whether that may be through mobile or console gameplay (https://ibn.fm/svMMr). Enhanced graphics, Gamification and AI-powered data analytics are fueling B2B and B2C growth in the fast-growing iGaming industry. Designed to appeal to users driven online due to COVID-19 restrictions, these technological enhancements promise to deliver an enhanced iGaming environment by simulating the actual real-world casino experience. iGaming growth is expected to continue increasing as a result. According to Grandview Research, total industry value is projected to reach 153.6 billion by 2030 at a CAGR of 11.7% from 2022 to 2030 (https://ibn.fm/fG1q7). Additionally, enhanced regulation is expected to attract more users as regulatory bodies issue licenses and impose fines on operators engaging in malpractice. GMGI is completely on board with technological innovation, offering highly configurable, modular, white-label, and turnkey gaming platforms compatible with all major operating systems, browsers, and devices. With a portfolio exceeding 10,000+ games across 25+ providers, GMGI’s GM-X integration platform exceeds industry standards, offering its growing B2B client base more selection than nearly any other provider in the space. In addition, the company’s iGaming tech leverages AI to collect critical marketing data, including customer gaming style, time spent playing, and user preferences. GMGI’s financial results testify to the success of its growth strategy. The company recently reported 15 consecutive profitable quarters, topped off with 221% growth in Q2-2022 (https://ibn.fm/U7lNJ). “We are pleased with the financial results of our second quarter as a company with both B2B and B2C verticals,” said Golden Matrix CEO Brian Goodman. “We expect this third quarter and future quarters to generate increasing revenues and profits.” Golden Matrix Group is the leading provider of turnkey and white label gaming platforms, Esports technology, and gaming content. The company pioneers highly modular, configurable, and scalable AI-powered gaming platforms that work on all major operating systems and devices, offering partners a distinct competitive advantage in the iGaming industry. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Reports Growth, Ongoing Optimism for Natural Food Brands Amid Market Pressures

  • Plant-based foods investment company Eat Well Investment Group Inc. has positioned itself to respond to global food needs exacerbated by the COVID pandemic and the war in Ukraine, and it reports its subsidiaries are in the right place to help deal with food sector concerns
  • Eat Well recently announced its annual financial data and Q1 2022 data, showing its Amara baby food subsidiary achieved revenue gains of 320 percent this year over the previous year
  • The company also reported it is on target to achieve this year’s revenue goals of $90 million to $110 million
Fears that a recession will overtake the global economy have roiled the marketplace for weeks, although analysts see some optimism in consumers’ ongoing willingness to spend for concerts, movies, travel and other experiences people missed during the height of the pandemic (https://ibn.fm/2lnMe). Among industry sectors hit hardest by inflationary pressures, the Bureau of Labor Statistics recently noted that the cost of food away from home (restaurants and fast food)’s Consumer Price Index (“CPI”) rose 7.4 percent over the 12 months ended in May, but prices for food at home climbed even faster, rising 11.9 percent — “the largest 12-month increase since the period ending April 1979” (https://ibn.fm/Kbdhq). Amid the trend, consumers have also been troubled by shortages provoked by production problems exacerbated by the global COVID pandemic and now the war in Ukraine — particularly in the infant formula sector, with some pressure on pureed baby food production as well (https://ibn.fm/0vm48). Plant-based foods investment company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) is reporting positive news amid the challenges. Eat Well’s portfolio includes protein alternative (non-meat) foods and natural baby food brands, and distribution agreements with Walmart, Whole Foods, Amazon and other companies have helped Eat Well’s products find their place on consumers’ shelves. Eat Well’s President & CEO Marc Aneed recently was interviewed by The Market Herald (Canada)’s reporters at The Power Play, discussing the company’s financial filings for the Q1 2022 including the growth of its cash position from $545,976 to $5.5 million (https://ibn.fm/AhOms), and record Q1 profit for its wholly-owned subsidiary Belle Pulses of over CAD $2 million. “Even as the markets are challenged, we can report that Eat Well is growing its company assets,” Aneed said during the video interview (https://ibn.fm/S9wni). “(Subsidiary plant-based ingredients processor Belle Pulses) in particular is our food security play today globally. … Distributed in 35 countries and now more critical than ever because pulses are made in three places in the world — Ukraine, Saskatchewan and China, and unfortunately the Ukraine has become challenged. So Belle is fielding calls from around the world.” Belle Pulses has been expanding its production facility in response to the food security concerns arising from the war in Ukraine. The company produced about 90,000 metric tons of pea protein during 2021 but plans to boost that amount to nearly 100,000 metric tons, and will add an additional 15,000 metric tons of annual production through its United States facility. The company reported expectations early this year that revenues would reach the $100 million mark for it’s portfolio companies in 2022, and in June the release of Eat Well’s annual financial statement indicated the company was on target to achieve its revenue goals (https://ibn.fm/IWjBJ). Aneed said its subsidiary baby food brand Amara Organic Foods is in a good position to deal with the shortages that have plagued that industry the past few months. “Especially in the states, where infant formula has been emptied of shelves across the country, Amara couldn’t be more timely poised,” he said. “And so right now Amara is growing its basket of products with new flavors of their cereals, their toddler melts, doing it across the continent. … So Amara is well-positioned, is 100 percent plant-based, 100 percent organic, and I have to say 100 percent delicious.” For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

GeoSolar Technologies Inc. Is ‘One to Watch’

  • GeoSolar Technologies is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources
  • The company’s technology has been installed in multiple test homes in Colorado and achieved exceptional results
  • The GeoSolarPlus system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system
  • The company’s leadership team includes some of the world’s most experienced and respected leaders in the field of decarbonization and sustainable homes
  • GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering
GeoSolar Technologies (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home(R) system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels. In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy. GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (“HERS”) in the industry. GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular. GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (“SEC”) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock. The Decarbonization Movement Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions. U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models. GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate. GeoSolarPlus(R) The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system. Key benefits of the GSP system include:
  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future
Click here to learn more about how GeoSolarPlus works. Management Team The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes. Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company. Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project. Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens. Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia. Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois. * Must be over 18, certain states are not currently available and will be added soon. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Enhances Bioavailability of Orally Administered APIs

  • Lexaria is a global innovator in drug delivery platforms
  • The company has developed the patented DehydraTECH(TM) technology that significantly improves the bioavailability of orally administered pharmaceuticals and therapeutics
  • Bioavailability is the fraction of a drug that reaches the site of action or systemic circulation
  • While drugs delivered intravenously are 100% bioavailable, drugs that have any other route of administration, such as oral, have reduced bioavailability
  • DehydraTECH enhances the bioavailability of APIs, in part, by bypassing first-pass liver processing
Global innovator Lexaria Bioscience (NASDAQ: LEXX) has built a reputation as a developer of drug delivery platforms, the most notable of which is the patented DehydraTECH(TM) technology. DehydraTECH is a formulation and dehydration processing method that modifies how the body detects and absorbs drugs, solving a glaring problem that has long affected orally administered drugs: low bioavailability. Bioavailability indicates the fraction or rate of the initial dose of a drug that is successfully made available to the site of action or systemic circulation (blood supply to all body tissues) from where target organs can readily access. “Intravenous dosing is considered 100% bioavailable since the drug is administered directly to the bloodstream, also termed the central compartment or systemic circulation. However, if a drug has some different route of administration, oral being most commonly employed, its bioavailability may be limited,” explains an article by the North East Biolab (https://ibn.fm/FroKl). “For oral doses, bioavailability limitations are typically due to the first-pass metabolism produced by the liver as well as incomplete absorption in the gut.” DehydraTECH solves the low bioavailability problem through a sophisticated API-delivery mechanism. According to Lexaria, DehydraTECH “works symbiotically with existing physiology systems to enable improved and more rapid absorption into the bloodstream and brain tissues.” The technology, which combines fat-soluble active pharmaceutical ingredients (“APIs”) with long-chain fatty acids, ensures the orally administered DehydraTECH-enabled API enters the upper intestine only minutes after administration. Next, the API is “delivered into the lymphatic lacteals primarily and transported across the upper intestinal wall – instead of going into the hepatic vein destined for the liver.” This way, the APIs bypass first-pass liver processing. In addition to increasing bioavailability, DehydraTECH offers additional benefits. Lexaria’s subjective and objective testing and pharmacokinetic studies conducted since 2015, for instance, show that DehydraTECH delivers higher quantities of APIs in less time – it is faster and more effective at delivering drugs into the bloodstream and brain tissue. More specifically, the technology increases bioavailability, improves the speed of onset, enhances brain absorption, and increases the ratio of drug delivery, which is expected to reduce drug administration costs by lowering the dosing. Furthermore, DehydraTECH masks unwanted taste, effectively dealing with the bitter, unpleasant taste of medicine and APIs that makes them aversive to children and even adults (https://ibn.fm/obdeJ). DehydraTECH, which is applied to various ingestible product formats, including mouth melts, oral suspensions, capsules, tablets, and others, has multiple opportunities for success in different APIs. To that end, Lexaria is actively developing lead product pipeline candidates in the areas of antiviral drugs, cannabidiol (“CBD”) for hypertension, and oral nicotine. The company also partners with third-party companies looking to explore formulation opportunities with their specific APIs of interest. Anchored in exclusive or non-exclusive licensing agreements, these partnerships boost Lexaria’s commercial prospects, given it grants the out-licenses in exchange for up-front fees, milestone payments, and/or royalty payments. But as CEO Chris Bunka emphasized in a January 2022 letter to shareholders (https://ibn.fm/e83eT), these current revenue streams, while important, are not the company’s main area of business focus. Rather, Lexaria is focused on “larger national and international applications for DehydraTECH, primarily but not entirely in the pharmaceutical sector.” For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.